- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024.
EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024
EP: 2.Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
EP: 3.MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
EP: 4.Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
EP: 5.ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone
EP: 6.Future Directions in the Management of Multiple Myeloma
Video content above is prompted by the following questions:
1. Discuss the data presented at ASCO 2024 on long-term follow-up of patients receiving prophylactic tocilizumab for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study.
a. What is the background for using tocilizumab prior to administration of bispecific antibodies?
b. What methodology was used to study this cohort of patients?
c. What results were presented?
i. N=24
ii. Median follow-up: 8.1 months
iii. CRS occurred in 6 pts (25%; 2 grade 1, 4 grade 2, no grade ≥3)
iv. Reduced incidence of CRS with teclistamab vs overall MajesTEC-1 population
2. Please provide your key takeaways from this study. What are the implications of favorable safety results with the use of prophylactic tocilizumab?
3. In what patients are you currently using prophylactic tocilizumab? Who should be considered for it?
Early Data Show Promising Outcomes as CAR T-Cell Therapy Expands Beyond Academic Centers
January 12th 2026Abstracts presented at ASH 2025 explore CAR T-cell therapy's effectiveness in newly authorized treatment centers, revealing promising outcomes for multiple myeloma patients and the prospect of expanded access.
Read More
